Aneurysm

61

Pipeline Programs↗

26

Active Trials↗

33

Companies Involved↗

Aneurysm is a moderately active landscape with 61 programs across 33 companies. The most active players are Pfizer, Regeneron, Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. 15 therapies are approved with 8 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

65/100

Pipeline Velocity

34/100

Mech. Concentration

6/100

Completion Rate

79/100

Attrition Rate

9/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved

Phase 3

Phase 2

Phase 1

Preclinical

Key Players

Top Companies

Pfizer

1 program

Regeneron

1 program

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

3 programs

RSPR Pharma AB

1 program

Prism Pharmaceuticals

1 program

Amgen

1 program

Pipeline

Programs by Phase

Preclinical19

Heparin

Baxter Healthcare Corporation

Atenolol

Twinpig Biolab, Inc.

Dexmedetomidine

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Ropivacaine

Fresenius Kabi Oncology Ltd.

Propofol

Fresenius Kabi Oncology Ltd.

Phase 13

Methylprednisolone

Pfizer

Aflibercept

Regeneron

Regional Anesthetic SPG Block-Bilateral

Mayo Clinic

Phase 216

Sirolimus

Prism Pharmaceuticals

Doxycycline

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Denosumab

Amgen

Infliximab

Organon and Co

Levosimendan

Orion Corporation, Orion Pharma

Phase 38

Ticagrelor

AstraZeneca

Acetaminophen

Kenvue Brands

Aspirin

Bayer

Magnesium Sulfate

Fresenius Kabi Oncology Ltd.

Simvastatin

Organon and Co

Approved15

Dimethyl Fumarate

Biogen

Rivaroxaban

Wim Janssens

Prasugrel

Cosette Pharmaceuticals, Inc.

Warfarin

Abbott

Clopidogrel

Sanofi

Analysis

Modality Breakdown

93%

Small molecule

64 of 69 classified programs — the dominant modality here.

Small molecule leads; the ring shows all 69 classified programs, each share of the total. Modality classified for 100% of 72 pipeline programs.

Analysis

Trial Status

82

clinical trials

Completed27 · 33%

Unknown status22 · 27%

Recruiting19 · 23%

Not yet recruiting5 · 6%

Withdrawn4 · 5%

Terminated3 · 4%

Other2 · 2%

Clinical Trials

Trial Activity

82 trials

Stent-Assisted Coiling Followed by Ticagrelor Monotherapy Instead of Dual Antiplatelet Therapy in Unruptured Intracranial Aneurysm

Recruiting·TThe First Affiliated Hospital with Nanjing Medical University·N/A·NCT06015477·180 enrolled

Levosimendan as Treatment of Aneurysmal SubArachnoid Haemorrhage

Recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 2·NCT05664191·30 enrolled

Early Lumbar Drainage Combined With Intrathecal Urokinase Injection for Treatment of Severe Aneurysmal SAH (LD-ITUK)

Recruiting·SSecond Affiliated Hospital of Nanchang University·Phase 4·NCT06284642·424 enrolled

Effect of Sirolimus on Molecular Alterations in Cerebral Aneurysms

Recruiting·UUniversity of Miami·Phase 2·NCT04141020·80 enrolled

Model-informed Dose Optimization for Rivaroxaban in Children With Giant Coronary Artery Aneurysm After Kawasaki Disease

Recruiting·—·Phase 4·NCT06978439·10 enrolled

FLudrocortisone Administration in Aneurysmal Subarachnoid Haemorrhage

Recruiting·TThe George Institute·Phase 2·NCT06409364·524 enrolled

INdobufen Versus asPirin in Endovascular Unruptured Intracranial Aneurysms Treatment (INPUT)

Recruiting·—·N/A·NCT07089862·2,500 enrolled

Prospective, Post-registration, Interventional, Randomized, in Parallel Groups, Multicenter Eurasian Clinical Study of DERIVO®/DERIVO® Mini Aneurysm Embolization Device, Europe-Asia

Recruiting·Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health·Phase 4·NCT06400940·640 enrolled

Metformin in Patients with Unruptured Vertebrobasilar Dissecting Aneurysms (METTLE)

Recruiting·—·N/A·NCT06405971·60 enrolled

Infliximab Therapy for Dolichoectactic Vertebrobasilar Aneurysms

Recruiting·UUniversity of California, San Francisco·Phase 1/2·NCT02638701·8 enrolled

A Prospective, Multi-center Clinical Study to Evaluate the Safety and Effectiveness of Arcevo LSA in the Open Repair of Aortic Arch Aneurysms and Dissections

Recruiting·AArtivion Inc.·Preclinical·NCT07089576·132 enrolled

Outcomes of Intra-arterial and Endosaccular Flow Diverters for Treatment of Intracranial Aneurysms - International Registry of Intra-arterial and Endosaccular Flow Diverters (IRF)

Recruiting·MMontefiore Medical Center·N/A·NCT06174727·5,000 enrolled

A Multicenter, Prospective, Single-Arm Observational Study to Evaluate the Safety and Effectiveness of the Choydar Flow-Directed Mesh Stent in the Treatment of Unruptured Intracranial Aneurysms

Recruiting·JJohnson & Johnson Medical (Shanghai) Ltd.·N/A·NCT07228312·200 enrolled

Safety and Efficacy Analysis of Stent-assisted Coil Embolization in the Treatment of Acute Ruptured Intracranial Aneurysms in the Perioperative Period.

Recruiting·TTang-Du Hospital·Preclinical·NCT07683377·174 enrolled

Prospective Randomized Controlled Trial of Surface-Modified Flow Diverter for Intracranial Aneurysms: Multicenter Assessment of Ischemic and Clinical Outcomes

Recruiting·HHenan Provincial People's Hospital·Preclinical·NCT07674004·196 enrolled

Page 1 of 6

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)